سعر تيموزولوميد اكورد 5مجم 5 كبسول 2022

Temozolomide 5 mg hard capsules (Accord Healthcare Limited / United Group Pharmaceutical (U.G.P.)); pack of 5 capsules.

• Adults with newly-diagnosed glioblastoma multiforme, concomitantly with radiotherapy and subsequently as monotherapy.European Medicines Agency (EMA)
• Children from 3 years, adolescents and adults with malignant glioma (e.g. glioblastoma multiforme or anaplastic astrocytoma) recurring or progressing after standard therapy.European Medicines Agency (EMA)

• Very common: anorexia, convulsions, hemiparesis, aphasia, headache, nausea, vomiting, diarrhoea, constipation, rash, alopecia, fatigue.International label, same formulation · European Medicines Agency (EMA)

• Hypersensitivity to temozolomide, any excipient or dacarbazine (DTIC); severe myelosuppression.International label, same formulation · European Medicines Agency (EMA)

• Pneumocystis jirovecii pneumonia prophylaxis is required during the 42-day concomitant radiotherapy regimen; opportunistic infections and HBV/CMV reactivation reported.International label, same formulation · European Medicines Agency (EMA)
• Hepatotoxicity including fatal hepatic failure; myelosuppression including prolonged pancytopenia/aplastic anaemia; myelodysplastic syndrome and secondary malignancies reported very rarely.International label, same formulation · European Medicines Agency (EMA)

• Valproic acidCo-administration associated with a small but statistically significant decrease in temozolomide clearance.European Medicines Agency (EMA)
• Other myelosuppressive agentsCombination may increase the likelihood of myelosuppression.European Medicines Agency (EMA)

• No data in pregnant women; teratogenic/foetotoxic in animals. Should not be given to pregnant women. Women of child-bearing potential must use effective contraception during and for at least 6 months after treatment; men should not father a child for at least 3 months after the last dose.International label, same formulation · European Medicines Agency (EMA)
• Unknown whether excreted in human milk; breast-feeding should be discontinued during treatment.International label, same formulation · European Medicines Agency (EMA)